Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time-limited venetoclax/obinutuzumab treatment.

Dimou, Maria; Iliakis, Theodoros; Paradalis, Vasileios; Bitsani, Aikaterini; Kyrtsonis, Marie-Christine; Panayiotidis, Panayiotis

Dimou, Maria; Iliakis, Theodoros; Paradalis, Vasileios; Bitsani, Aikaterini; Kyrtsonis, Marie-Christine; Panayiotidis, Panayiotis.

Afiliação

Dimou M; First Department of Internal Medicine, Propaedeutic, Hematology Clinical Trial Unit Laiko General Hospital Athens Greece.
Iliakis T; First Department of Internal Medicine, Propaedeutic, Hematology Clinical Trial Unit Laiko General Hospital Athens Greece.
Paradalis V; First Department of Internal Medicine, Propaedeutic, Hematology Clinical Trial Unit Laiko General Hospital Athens Greece.
Bitsani A; First Department of Internal Medicine, Propaedeutic, Hematology Clinical Trial Unit Laiko General Hospital Athens Greece.
Kyrtsonis MC; First Department of Internal Medicine, Propaedeutic, Hematology Clinical Trial Unit Laiko General Hospital Athens Greece.
Panayiotidis P; First Department of Internal Medicine, Propaedeutic, Hematology Clinical Trial Unit Laiko General Hospital Athens Greece.

Clin Case Rep ; 9(7): e04514, 2021 Jul.

Article em En | MEDLINE | ID: mdl-34322260

ABSTRACT

ABSTRACT

The novel time-limited combinations with the bcl-2 inhibitor venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient.

Palavras-chave

CLL/SLL; MRD negativity; skin nodules; timelimited treatment; venetoclax

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links